Cargando…

SSRIs treatment did not completely restore affective state in patients with the initial clinically confirmed major depressive disorder/generalized anxiety disorder after COVID-19 disease

INTRODUCTION: The major clinical outcomes of COVID-19 in the brain are associated with its deleterious neurological and mental health actions. Today, there are limited findings concerning the studying of neuropsychiatric action for SARS-Cov-2 in humans after COVID-19 disease. OBJECTIVES: The aim of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fedotova, J., Bereza, Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2022
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9566958/ http://dx.doi.org/10.1192/j.eurpsy.2022.279

Ejemplares similares

P.0403 Disticnt effects of SSRIs therapy in patients with the first episode of major depressive disorder/generalized anxiety disorder after COVID-19 disease
por: Bereza, Z., et al.
Publicado: (2021)

Resveratrol supplementation enhanced SSRIs efficacy in premenopausal women with major depressive disorder
por: Fedotova, J., et al.
Publicado: (2023)

Usefulness of LDAEP to Predict Tolerability to SSRIs in Major Depressive Disorder: A Case Report
por: Park, Young-Min, et al.
Publicado: (2012)

Effect of SSRIs on Resting-State Functional Brain Networks in Adolescents with Major Depressive Disorder
por: Chu, Shu-Hsien, et al.
Publicado: (2021)

Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder
por: Lundberg, Johan, et al.
Publicado: (2012)

Relationship between SSRIs and Metabolic Syndrome Abnormalities in Patients with Generalized Anxiety Disorder: A Prospective Study
por: Beyazyüz, Murat, et al.
Publicado: (2013)

Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder
por: Liu, Xianchen, et al.
Publicado: (2011)

Disorder-specific cognitive profiles in major depressive disorder and generalized anxiety disorder
por: Hendriks, Sanne M, et al.
Publicado: (2014)

A MRS study of metabolic alterations in the frontal white matter of major depressive disorder patients with the treatment of SSRIs
por: Zhang, Yifan, et al.
Publicado: (2015)

The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
por: Fugger, Gernot, et al.
Publicado: (2022)

Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder
por: Muscatello, Maria Rosaria Anna, et al.
Publicado: (2019)

Are Worry and Rumination Specific Pathways Linking Neuroticism and Symptoms of Anxiety and Depression in Patients with Generalized Anxiety Disorder, Major Depressive Disorder and Mixed Anxiety-Depressive Disorder?
por: Merino, Hipólito, et al.
Publicado: (2016)

Data on the impact of SSRIs and depression symptoms on the neural activities in obsessive–compulsive disorder at rest
por: Chen, Yunhui, et al.
Publicado: (2016)

Resting-State fMRI in Predicting Response to Treatment With SSRIs in First-Episode, Drug-Naive Patients With Major Depressive Disorder
por: Zhang, Aixia, et al.
Publicado: (2022)

New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
por: Baune, Bernhard T
Publicado: (2008)

Hemolacria secondary to major depressive disorder and generalized anxiety disorder: A case report
por: Razeghian Jahromi, Leila, et al.
Publicado: (2023)

Repeated use of SSRIs potentially associated with an increase on serum CK and CK-MB in patients with major depressive disorder: a retrospective study
por: Wu, Shengwei, et al.
Publicado: (2021)

TED—trazodone effectiveness in depression: a naturalistic study of the effeciveness of trazodone in extended release formulation compared to SSRIs in patients with a major depressive disorder
por: Dudek, Dominika, et al.
Publicado: (2023)

Comorbid generalized anxiety disorder and its association with quality of life in patients with major depressive disorder
por: Zhou, Yongjie, et al.
Publicado: (2017)

Evaluation of depression and anxiety control in greek patients with major depressive disorder with/without generalized anxiety disorder and cardiovascular disease–pronoi study
por: Papanastasiou, P., et al.
Publicado: (2021)

PS98. Do SSRIs cause an initial increase in suicidal ideation and anxiety in patients with depression participating in placebo-controlled trials?
por: Näslund, Jakob
Publicado: (2016)

Acupuncture combined with SSRIs in the treatment of perimenopausal depressive disorder: A protocol for systematic review and meta-analysis
por: Gao, Zhan, et al.
Publicado: (2022)

Gut Microbiome: A Potential Indicator for Differential Diagnosis of Major Depressive Disorder and General Anxiety Disorder
por: Dong, Zaiquan, et al.
Publicado: (2021)

Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study
por: Christensen, Michael Cronquist, et al.
Publicado: (2022)

Differentiation value of miR-26b for major depressive disorder, schizophrenia, generalized anxiety disorder
por: Kong, Lingming, et al.
Publicado: (2023)

The comparison of severity and prevalence of major depressive disorder, general anxiety disorder and eating disorders before and after bariatric surgery
por: Matini, Diana, et al.
Publicado: (2014)

A Markov Model Approach Assessing the Cost of Illness of Generalized Anxiety Disorder in Canada
por: Bereza, Basil G., et al.
Publicado: (2012)

Evaluation of Coronavirus Anxiety Levels and Coping Strategies of Major Depressive Disorder, Generalized Anxiety Disorder, and Panic Disorder Patients During the Covid-19 Pandemic
por: Erden, Selime Celik, et al.
Publicado: (2023)

Long noncoding RNAs: New evidence for overlapped pathogenesis between major depressive disorder and generalized anxiety disorder
por: Cui, Xuelian, et al.
Publicado: (2017)

Disorder- and emotional context-specific neurofunctional alterations during inhibitory control in generalized anxiety and major depressive disorder
por: Liu, Congcong, et al.
Publicado: (2021)

Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain
por: De Salas-Cansado, Marina, et al.
Publicado: (2012)

In-hospital predictors of post-stroke depression for targeted initiation of Selective Serotonin Reuptake Inhibitors (SSRIs)
por: Yi, Julie, et al.
Publicado: (2022)

Prospective mental imagery in patients with major depressive disorder or anxiety disorders
por: Morina, Nexhmedin, et al.
Publicado: (2011)

Risk Factors for Anxiety in Major Depressive Disorder Patients
por: Xin, Li-Min, et al.
Publicado: (2015)

Association between increased serum interleukin-8 levels and improved cognition in major depressive patients with SSRIs
por: Cai, Yuan, et al.
Publicado: (2023)

An audit assessing the monitoring of SSRIS after initiation in children and adolescents
por: McGowan, Ella
Publicado: (2021)

Attribution retraining group therapy for outpatients with major depression disorder, generalized anxiety disorder, and obsessive-compulsive disorder: a pilot study()
por: Wang, Chun, et al.
Publicado: (2011)

Major Depressive Episode and Generalized Anxiety Disorder Among Sexual Minority Adults in the United States
por: Exten, Cara, et al.
Publicado: (2020)

Emotional Roles of Mono-Aminergic Neurotransmitters in Major Depressive Disorder and Anxiety Disorders
por: Liu, Yi, et al.
Publicado: (2018)

Placental serotonin: implications for the developmental effects of SSRIs and maternal depression
por: Velasquez, Juan C., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_a9h0ee92a9ubdffc4ou6dru7d7